Go Pro
OTCMKTS:SEOVF

Sernova Biotherapeutics Q1 2026 Earnings Report

Sernova Biotherapeutics logo
$0.06 +0.00 (+3.06%)
As of 03:54 PM Eastern

Sernova Biotherapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.00
One Year Ago EPS
N/A

Sernova Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Biotherapeutics Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Sernova Biotherapeutics Earnings Headlines

Sernova Biotherapeutics Inc SEOVF
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Sernova Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova Biotherapeutics and other key companies, straight to your email.

About Sernova Biotherapeutics

Sernova Biotherapeutics (OTCMKTS:SEOVF) is a clinical-stage biotechnology company focused on developing regenerative medicine technologies for the treatment of chronic diseases. Its platform combines an implantable device, therapeutic cells and methods intended to protect transplanted cells from immune-system rejection.

The company’s primary technology is the Cell Pouch System, an implantable, vascularized device designed to house therapeutic cells and support their long-term function in the body. Sernova has investigated the platform for conditions including type 1 diabetes and hemophilia, with research involving insulin-producing islet cells and other cell-based therapies.

Sernova is based in London, Ontario, Canada, and has conducted research and clinical development activities in collaboration with academic and medical institutions. The company has been led by Philip Toleikis, who serves as president and chief executive officer. Its programs remain focused on advancing cell-based treatments toward potential clinical use.

View Sernova Biotherapeutics Profile